Jun. 1 at 10:08 PM
$CNTX $CNTX (Context Therapeutics) just received FDA Fast Track Designation for CTIM-76 in the treatment of platinum-resistant ovarian cancer.
Given this milestone, it makes little sense that the stock continues to trade in a bearish trend unless the market is significantly undervaluing the development or short-term price action is being driven by manipulation and sentiment rather than fundamentals.
What's even more interesting is that
$CNTX has been mirroring many of the same upward and downward trading patterns as
$ARDX, suggesting that broader market forces, algorithmic trading, or sector-wide pressure may be influencing the price more than company-specific news.
The fundamentals continue to improve, yet the share price has failed to reflect the progress. At some point, the disconnect between the company's achievements and its valuation will have to close.
